Prevalence of metabolic syndrome among pregnant women: a systematic review and meta-analysis.

IF 3.7 3区医学 Q2 Medicine Endocrine Pub Date : 2025-01-22 DOI:10.1007/s12020-025-04160-8

A Mohebi, M M Pathirana, A Khoja, M R Wittwer, K Lowe, D Fisher, S Kharwadkar, C Gomes, T Gamage, E Toyer, S Young, M A Arstall, P H Andraweera

{"title":"Prevalence of metabolic syndrome among pregnant women: a systematic review and meta-analysis.","authors":"A Mohebi, M M Pathirana, A Khoja, M R Wittwer, K Lowe, D Fisher, S Kharwadkar, C Gomes, T Gamage, E Toyer, S Young, M A Arstall, P H Andraweera","doi":"10.1007/s12020-025-04160-8","DOIUrl":null,"url":null,"abstract":"Purpose: Metabolic syndrome (MetS) is a cluster of risk factors that increase the risk of cardiometabolic diseases. The prevalence of MetS and individual components across pregnancy has not been reviewed in the literature. This research was conducted to identify the prevalence of MetS and its components among pregnant women.Methods: The PubMed, EMBASE, CINAHL, Web of Science and Scopus databases were searched. The review protocol is registered in PROSPERO (CRD42023460729). Quality assessment was performed using the JBI critical appraisal checklist. The study selection, data extraction and data analyses were performed in accordance with the MOOSE guidelines.Results: The prevalence of MetS among pregnant women was 16.3%, (n = 3946). The prevalences for individual MetS components were: low HDL, 12.3% (n = 1108); high fasting glucose, 16.2% (n = 2333); high triglycerides, 48.5% (n = 2880); obesity, 42.7% (n = 5162) and high blood pressure 37.7% (n = 828). According to the definitions used to diagnose MetS, the prevalences were 18.2% according to the World Health Organization, 15.0% according to the International Diabetes Federation and 17.2% according to the National Cholesterol Education Program Adult Treatment Panel III. When stratified by gestational age at assessment, the prevalence of MetS was 9.9% before 16 weeks' and 24.1% after 20 weeks' of gestation.Conclusion: This review demonstrates that MetS is detected in approximately one-fifth of pregnant women. Screening for MetS and its components during pregnancy may help identify young women at risk for future cardiovascular disease.","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-025-04160-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Metabolic syndrome (MetS) is a cluster of risk factors that increase the risk of cardiometabolic diseases. The prevalence of MetS and individual components across pregnancy has not been reviewed in the literature. This research was conducted to identify the prevalence of MetS and its components among pregnant women.

Methods: The PubMed, EMBASE, CINAHL, Web of Science and Scopus databases were searched. The review protocol is registered in PROSPERO (CRD42023460729). Quality assessment was performed using the JBI critical appraisal checklist. The study selection, data extraction and data analyses were performed in accordance with the MOOSE guidelines.

Results: The prevalence of MetS among pregnant women was 16.3%, (n = 3946). The prevalences for individual MetS components were: low HDL, 12.3% (n = 1108); high fasting glucose, 16.2% (n = 2333); high triglycerides, 48.5% (n = 2880); obesity, 42.7% (n = 5162) and high blood pressure 37.7% (n = 828). According to the definitions used to diagnose MetS, the prevalences were 18.2% according to the World Health Organization, 15.0% according to the International Diabetes Federation and 17.2% according to the National Cholesterol Education Program Adult Treatment Panel III. When stratified by gestational age at assessment, the prevalence of MetS was 9.9% before 16 weeks' and 24.1% after 20 weeks' of gestation.

Conclusion: This review demonstrates that MetS is detected in approximately one-fifth of pregnant women. Screening for MetS and its components during pregnancy may help identify young women at risk for future cardiovascular disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

孕妇代谢综合征的患病率：一项系统回顾和荟萃分析。

目的：代谢综合征（MetS）是一组增加心脏代谢疾病风险的危险因素。在整个妊娠期间，MetS和个体成分的患病率尚未在文献中进行审查。本研究旨在确定妊娠妇女中MetS的患病率及其组成部分。方法：检索PubMed、EMBASE、CINAHL、Web of Science、Scopus等数据库。审查方案已在PROSPERO注册（CRD42023460729）。使用JBI关键评估清单进行质量评估。根据MOOSE指南进行研究选择、数据提取和数据分析。结果：met在孕妇中的患病率为16.3% （n = 3946）。个体MetS成分的患病率为：低HDL， 12.3% (n = 1108)；空腹血糖高，16.2% (n = 2333)；高甘油三酯，48.5% (n = 2880)；肥胖占42.7% (n = 5162)，高血压占37.7% （n = 828）。根据用于诊断MetS的定义，根据世界卫生组织，患病率为18.2%，根据国际糖尿病联合会，患病率为15.0%，根据国家胆固醇教育计划成人治疗小组III，患病率为17.2%。当评估时按胎龄分层时，妊娠16周前的met患病率为9.9%，妊娠20周后为24.1%。结论：本综述显示约五分之一的孕妇检测到MetS。在怀孕期间筛查MetS及其成分可能有助于确定年轻女性未来患心血管疾病的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Endocrine 医学-内分泌学与代谢

CiteScore

6.40

自引率

5.40%

发文量

期刊介绍： Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology. Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted. Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.